How type I interferon affects lung cell recovery after injury
Modulation of Acute Lung Injury by Type I Interferon Signaling
This study is looking at how a specific signaling process in the lungs helps certain cells recover after an injury, which is important for healing, especially for people who have had conditions like COVID-19.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11040388 on NIH RePORTER |
What this research studies
This research investigates the role of type I interferon signaling in the recovery of lung cells after acute lung injury, particularly focusing on type 2 alveolar cells. The researchers aim to understand how this signaling pathway affects the proliferation of these cells, which is crucial for healing. Using advanced techniques like CRISPR screening, they will explore the molecular mechanisms involved and assess how this signaling may impact recovery from conditions like COVID-19. The findings could lead to new insights into lung regeneration and treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced acute lung injury or respiratory distress, particularly related to COVID-19.
Not a fit: Patients with chronic lung conditions or those who have not experienced acute lung injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies for patients suffering from acute lung injuries, including those caused by COVID-19.
How similar studies have performed: Other research has indicated that targeting cellular signaling pathways can significantly impact recovery from lung injuries, suggesting potential success for this approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Emmer, Brian T — University of Michigan at Ann Arbor
- Study coordinator: Emmer, Brian T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.